J Torrente Sierra | PubMed Health

PubMed1989

[Comments on the current treatment of fulminant liver failure].

The current treatment of fulminant liver failure, underscoring substitutive liver therapy, is reviewed. The usefulness of hemodialysis and hemofiltration with a high-permeability membrane, hemoperfusion with activated carbon, hemoperfusion with resins, plasma exchange, artificial cells and the combination of various techniques for the same patients has been studied. Finally, the indications for utility of these techniques and the role of liver transplantation are considered. Early onset of treatment is essential for achieving satisfactory results.

Hemofiltration↗

PubMed1982

[Periodic hemofiltration].

Explore the source record for details and available documents.

Adolescent↗

PubMed1979

[Result of the administration of high doses of bumetanide to patients with chronic renal failure who are on a program of hemodialysis (author's transl)].

High doses of furosemide were given to patients with chronic renal failure who were on a program of dialysis with the aim of achieving less frequent dialysis or a more liberal diet for these patients. The result of the oral administration of 12 mg of bumetanide per day in 12 patients with renal insufficiency submitted to periodic hemodialysis were evaluated. The residual renal function of these patients varied between 1.5 and 6 ml/min of creatinine clearance. A significant variation could not be established in the predialysis values of urea, creatinine or potassium, nor of the interdialysis weight increase, nor of the urinary excretion of Na and K. On the contrary, the predialysis natremia levels varied from 133 to 138 mEq/l (p less than 0.01) under the effect of the medication and this coincided with a significant increase of the diuresis. As secondary effect the authors frequently recorded myalgia of variable intensity without significant changes in the serum enzymes of muscular origin.

Administration, Oral↗